126 related articles for article (PubMed ID: 27146272)
1. Relationship of diastolic function to new or persistent electrocardiographic left ventricular hypertrophy.
Tanoue MT; Kjeldsen SE; Devereux RB; Okin PM
Blood Press; 2016 Dec; 25(6):364-372. PubMed ID: 27146272
[TBL] [Abstract][Full Text] [Related]
2. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
[TBL] [Abstract][Full Text] [Related]
3. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
Bang CN; Devereux RB; Okin PM
J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
[TBL] [Abstract][Full Text] [Related]
4. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
5. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
[TBL] [Abstract][Full Text] [Related]
6. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
[TBL] [Abstract][Full Text] [Related]
7. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation.
Okin PM; Gerdts E; Wachtell K; Oikarinen L; Nieminen MS; Dahlöf B; Devereux RB
J Hypertens; 2010 Jul; 28(7):1534-40. PubMed ID: 20589977
[TBL] [Abstract][Full Text] [Related]
8. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
Okin PM; Devereux RB; Jern S; Julius S; Kjeldsen SE; Dahlöf B
Am J Hypertens; 2001 Aug; 14(8 Pt 1):775-82. PubMed ID: 11497193
[TBL] [Abstract][Full Text] [Related]
9. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Dahlöf B
Hypertension; 2000 Nov; 36(5):766-73. PubMed ID: 11082141
[TBL] [Abstract][Full Text] [Related]
10. Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
Okin PM; Hille DA; Kjeldsen SE; Devereux RB
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151037
[TBL] [Abstract][Full Text] [Related]
11. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
Okin PM; Devereux RB; Liu JE; Oikarinen L; Jern S; Kjeldsen SE; Julius S; Wachtell K; Nieminen MS; Dahlöf B
J Hum Hypertens; 2004 Jun; 18(6):403-9. PubMed ID: 15057252
[TBL] [Abstract][Full Text] [Related]
12. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
Okin PM; Jern S; Devereux RB; Kjeldsen SE; Dahlöf B;
Hypertension; 2000 Jan; 35(1 Pt 1):13-8. PubMed ID: 10642268
[TBL] [Abstract][Full Text] [Related]
13. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B;
Ann Intern Med; 2007 Sep; 147(5):311-9. PubMed ID: 17785486
[TBL] [Abstract][Full Text] [Related]
14. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
Okin PM; Hille DA; Kjeldsen SE; Lindholm LH; Edelman JM; Dahlöf B; Devereux RB
Am J Hypertens; 2010 Jul; 23(7):786-93. PubMed ID: 20395941
[TBL] [Abstract][Full Text] [Related]
15. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Okin PM; Wachtell K; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Lindholm LH; Nieminen MS; Edelman JM; Hille DA; Dahlöf B
JAMA; 2006 Sep; 296(10):1242-8. PubMed ID: 16968848
[TBL] [Abstract][Full Text] [Related]
16. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Wachtell K; Bella JN; Rokkedal J; Palmieri V; Papademetriou V; Dahlöf B; Aalto T; Gerdts E; Devereux RB
Circulation; 2002 Mar; 105(9):1071-6. PubMed ID: 11877357
[TBL] [Abstract][Full Text] [Related]
17. Relationship between abnormal P-wave terminal force in lead V
Tanoue MT; Kjeldsen SE; Devereux RB; Okin PM
Blood Press; 2017 Apr; 26(2):94-101. PubMed ID: 27601135
[TBL] [Abstract][Full Text] [Related]
18. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
[TBL] [Abstract][Full Text] [Related]
19. Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy.
Okin PM; Gerdts E; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B; Devereux RB;
Hypertension; 2008 Jul; 52(1):100-6. PubMed ID: 18504323
[TBL] [Abstract][Full Text] [Related]
20. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
